Abemaciclib metabolite M18-d8

Abemaciclib metabolite M18-d8

• Product Name Alternative: LSN3106729-d8
• UNSPSC Description: Abemaciclib metabolite M18-d8 is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1][2].
• Target Antigen: CDK; Ligands for Target Protein for PROTAC
• Type: Isotope-Labeled Compounds
• Related Pathways: Cell Cycle/DNA Damage;PROTAC
• Field of Research: Cancer
• Purity: 99.87
• Solubility: DMSO : 32 mg/mL (ultrasonic)
• Smiles: FC(C=N1)=C(C2=CC(N(C(C)C)C(CO)=N3)=C3C(F)=C2)N=C1NC4=NC=C(C=C4)CN5C([2H])([2H])C([2H])([2H])NC([2H])([2H])C5([2H])[2H]
• Molecular Weight: 502.59
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Nathanael Gray, et al. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use. WO2017185031A1.|[3]Edward S. Kim, et al. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: No Development Reported